Please assess the completion status of the following clinical trial:

Trial Title: Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with the clinical diagnosis of localization related epilepsy/focal seizure (International League Against Epilepsy 2010) with a history of an episode of seizure within 48 hours of presentation~* Treatment naïve patients or patients who had not taken any treatment for at least 3 weeks before inclusion.~Exclusion Criteria:~* History of any recent traumatic brain injury, cerebral ischemia/transient ischemic attack/stroke~* Patients with neuroendocrinal tumours~* History of any invasive neurosurgical /non-invasive neuropsychiatric procedure.~* Patients who are already under treatment for the presenting conditions.~* Medication history of psychoactive or central nervous system depressant drugs~* Pregnant and nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Healthy control (Type: NO_INTERVENTION): Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
- Carbamazepine group (Type: EXPERIMENTAL): Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
- Oxcarbazepine group (Type: EXPERIMENTAL): Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).